Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 39.32% is in line with its 5-year average of 36.69%, around the middle of its 5-year range (30.99%–44.31%).
0.33% below its 12-month average of 39.45%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 42.01%.
GROSS MARGIN
39.32%
GROSS MARGIN AVG TTM
39.45%
GROSS MARGIN AVG 3Y
36.78%
GROSS MARGIN AVG 5Y
36.69%
GROSS MARGIN AVG 10Y
37.43%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.33%
CURRENT VS 3Y AVG
+6.90%
CURRENT VS 5Y AVG
+7.17%
CURRENT VS 10Y AVG
+5.04%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.94%
median of 744 covered companies
CURRENT VS SECTOR MEDIAN
-1.55%
vs the sector median at left
Amneal Pharmaceuticals, Inc.
Market Cap
$6.52B
Gross Margin
39.32%
TTM Avg
39.45%
3Y Avg
36.78%
5Y Avg
36.69%
Market Cap
$6.51B
Gross Margin
60.14%
TTM Avg
62.77%
3Y Avg
60.62%
5Y Avg
54.58%
Market Cap
$6.53B
Gross Margin
73.84%
TTM Avg
76.65%
3Y Avg
78.21%
5Y Avg
76.94%
Market Cap
$6.36B
Gross Margin
89.00%
TTM Avg
89.73%
3Y Avg
89.61%
5Y Avg
73.24%
Market Cap
$5.95B
Gross Margin
98.58%
TTM Avg
95.46%
3Y Avg
84.33%
5Y Avg
82.16%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.52B | 39.32% | 39.45% | 36.78% | 36.69% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 60.14% | 62.77% | 60.62% | 54.58% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.53B | 73.84% | 76.65% | 78.21% | 76.94% |
| Immunovant, Inc. (IMVT)vs › | $6.63B | 0.00% | 0.00% | 0.00% | 0.00% |
| Chemed Corporation (CHE)vs › | $6.67B | 30.44% | 32.55% | 34.06% | 34.32% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.36B | 89.00% | 89.73% | 89.61% | 73.24% |
| GRAIL Inc. (GRAL)vs › | $5.94B | -42.52% | -52.32% | -104.24% | -183.56% |
| Alkermes plc (ALKS)vs › | $7.04B | 84.56% | 85.47% | 84.03% | 83.69% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 98.58% | 95.46% | 84.33% | 82.16% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.87B | 97.23% | 60.83% | -170.72% | -113.81% |
Gross Margin
39.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 42.01% |
| 2026-03-31 | 44.31% |
| 2025-12-31 | 36.50% |
| 2025-09-30 | 34.92% |
| 2025-06-30 | 39.51% |
| 2025-03-31 | 36.80% |
| 2024-12-31 | 35.98% |
| 2024-09-30 | 38.37% |
| 2024-06-30 | 35.62% |
| 2024-03-31 | 36.11% |
| 2023-12-31 | 36.55% |
| 2023-09-30 | 37.50% |
| 2023-06-30 | 36.73% |
| 2023-03-31 | 31.96% |
| 2022-12-31 | 35.32% |
| 2022-09-30 | 35.60% |
| 2022-06-30 | 35.85% |
| 2022-03-31 | 35.08% |
| 2021-12-31 | 30.99% |
| 2021-09-30 | 37.55% |
| 2021-06-30 | 39.71% |
| 2021-03-31 | 38.85% |
| 2020-12-31 | 32.76% |
| 2020-09-30 | 25.72% |
| 2020-06-30 | 31.04% |
| 2020-03-31 | 36.81% |
| 2019-12-31 | 27.74% |
| 2019-09-30 | 14.39% |
| 2019-06-30 | 26.01% |
| 2019-03-31 | 18.62% |
| 2018-12-31 | 38.87% |
| 2018-09-30 | 42.00% |
| 2018-06-30 | 43.09% |
| 2018-03-31 | 52.54% |
| 2017-12-31 | 51.61% |
| 2017-09-30 | 53.00% |
| 2017-06-30 | 47.61% |
| 2017-03-31 | 48.67% |
| 2016-12-31 | 59.16% |
